Histamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
Histamine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Histamine Receptors [75, 163]) are activated by the endogenous ligand histamine. Marked species differences exist between histamine receptor orthologues . The human and rat H3 receptor genes are subject to significant splice variance . The potency order of histamine at histamine receptor subtypes is H3 = H4 > H2 > H1 . Some agonists at the human H3 receptor display significant ligand bias . Antagonists of all 4 histamine receptors have clinical uses: H1 antagonists for allergies (e.g. cetirizine), H2 antagonists for acid-reflux diseases (e.g. ranitidine), H3 antagonists for narcolepsy (e.g. pitolisant/WAKIX; Registered) and H4 antagonists for atopic dermatitis (e.g. ZPL-3893787; Phase IIa)  and vestibular neuritis (AUV) (SENS-111 (Seliforant, previously UR-63325), entered and completed vestibular neuritis (AUV) Phase IIa efficacy and safety trials, respectively) [205, 8].
How to Cite
Chazot, P., Cowart, M., Fukui, H., Ganellin, C. R., Gutzmer, R., Haas, H. L., Hill, S. J., Hills, R., Leurs, R., Levi, R., Liu, S., Panula, P., Schunack, W., Schwartz, J.-C., Seifert, R., Shankley, N. P., Stark, H., Thurmond, R., Timmerman, H. and Young, J. M. (2019) “Histamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database”, IUPHAR/BPS Guide to Pharmacology CITE, 2019(4). doi: 10.2218/gtopdb/F33/2019.4.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.